Markets

Biodesix Announces Progress In Two Collaborative Programs For Tumor-informed And Tumor-naïve Molecular Residual Disease Solutions

Sep 24, 2026 · 06:36 AM ET· updated 1h ago

Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve Molecular Residual Disease (MRD) solutions

Why It Matters

Biodesix is working on two new blood test projects. These tests might find cancer leftover after treatment, which doctors want to catch early.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BDSX28.70

-0.59 (-2.03%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.